Finally, recent clinical trials testing the safety and efficacy of monoclonal antibodies targeting IL-17A and IL-23 in SpA, psoriasis, psoriatic arthritis and Crohn's disease have been very encouraging and have increased the therapeutic options for these diseases. This evidence concerns the gene IL17A and psoriatic arthritis.